Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
Study Details
Study Description
Brief Summary
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: bimatoprost Formulation A Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months. |
Drug: bimatoprost Formulation A
Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
|
Experimental: bimatoprost Formulation B Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months. |
Drug: bimatoprost Formulation B
Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
|
Experimental: bimatoprost Formulation C Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months. |
Drug: bimatoprost Formulation C
Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
|
Placebo Comparator: bimatoprost vehicle solution Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months. |
Drug: bimatoprost vehicle solution
Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
|
Active Comparator: minoxidil 5% solution Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months. |
Drug: minoxidil 5% solution
Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change From Baseline in Target Area Hair Count (TAHC) [Baseline, Month 6]
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs).
- Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score [Baseline, Month 6]
The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: "Since the start of the study, the amount of my hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.
Secondary Outcome Measures
- Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score [Baseline, Month 6]
The investigator compared the participant's scalp hair growth at Month 6 to a photograph of the scalp taken at Baseline and using the 7-point IGA score, the investigator answered the question: "Since the start of the study, the amount of the subject's hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.
- Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score [Baseline, Month 6]
At the completion of the study, 3 independent dermatologists using the 7-point GPR score compared photographs of the participant's scalp hair growth at Month 6 to Baseline and answered the question: "Compared with the baseline image, the amount of the subject's hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.
- Change From Baseline in Target Area Hair Width (TAHW) [Baseline, Month 6]
Digital imaging analysis was used to measure TAHW in millimeters/centimeters squared (mm/cm^2). The diameters of all terminal hairs (individual hairs ≥ 30 microns in width) in the target area were summed and reported together. A positive change from Baseline indicated improvement (increase in the diameter of terminal hairs).
- Change From Baseline in Target Area Hair Darkness (TAHD) [Baseline, Month 6]
Digital imaging analysis was used to measure TAHD. The darkness of all terminal hairs (individual hairs ≥ 30 microns in width) in the target area were summed and divided by total number of terminal hairs in the same target area and was reported as intensity units. A positive change from Baseline indicated improvement (increase in the darkness of terminal hairs).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year
-
Willingness to have micro-dot-tattoo applied to scalp
-
Willingness to maintain same hair style, length and hair color during study
Exclusion Criteria:
-
Drug or alcohol abuse within 12 months
-
HIV positive
-
Received hair transplants or had scalp reductions
-
Use of hair weaves, hair extensions or wigs within 3 months
-
Oral or topical minoxidil treatment within 6 months
-
Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Portland | Oregon | United States | ||
2 | Berlin | Germany |
Sponsors and Collaborators
- Allergan
Investigators
- Study Director: Medical Director, Allergan
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 192024-057
- 2011-000379-15
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution |
---|---|---|---|---|---|
Arm/Group Description | Approximately one milliliter (mL) of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of minoxidil 5% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months. |
Period Title: Overall Study | |||||
STARTED | 61 | 61 | 62 | 62 | 61 |
COMPLETED | 56 | 52 | 53 | 52 | 53 |
NOT COMPLETED | 5 | 9 | 9 | 10 | 8 |
Baseline Characteristics
Arm/Group Title | Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution | Total |
---|---|---|---|---|---|---|
Arm/Group Description | Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of minoxidil 5% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months. | Total of all reporting groups |
Overall Participants | 61 | 61 | 62 | 62 | 61 | 307 |
Age, Customized (Number) [Number] | ||||||
18 to 34 years |
19
31.1%
|
18
29.5%
|
20
32.3%
|
18
29%
|
18
29.5%
|
93
30.3%
|
35 to 50 years |
42
68.9%
|
43
70.5%
|
42
67.7%
|
44
71%
|
43
70.5%
|
214
69.7%
|
Sex: Female, Male (Count of Participants) | ||||||
Female |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
Male |
61
100%
|
61
100%
|
62
100%
|
62
100%
|
61
100%
|
307
100%
|
Outcome Measures
Title | Change From Baseline in Target Area Hair Count (TAHC) |
---|---|
Description | TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs). |
Time Frame | Baseline, Month 6 |
Outcome Measure Data
Analysis Population Description |
---|
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure. |
Arm/Group Title | Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution |
---|---|---|---|---|---|
Arm/Group Description | Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of minoxidil 5% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months. |
Measure Participants | 60 | 61 | 61 | 61 | 61 |
Baseline |
135.0
(58.80)
|
145.7
(57.25)
|
151.5
(60.40)
|
143.7
(55.42)
|
132.7
(53.14)
|
Change from Baseline at Month 6 |
13.1
(21.69)
|
6.1
(19.80)
|
6.3
(22.05)
|
4.1
(15.59)
|
21.9
(19.30)
|
Title | Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score |
---|---|
Description | The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: "Since the start of the study, the amount of my hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented. |
Time Frame | Baseline, Month 6 |
Outcome Measure Data
Analysis Population Description |
---|
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure. |
Arm/Group Title | Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution |
---|---|---|---|---|---|
Arm/Group Description | Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of minoxidil 5% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months. |
Measure Participants | 58 | 59 | 60 | 58 | 58 |
Greatly Increased |
0.0
0%
|
1.7
2.8%
|
0.0
0%
|
1.7
2.7%
|
5.2
8.5%
|
Moderately Increased |
8.6
14.1%
|
11.9
19.5%
|
11.7
18.9%
|
6.9
11.1%
|
27.6
45.2%
|
Slightly Increased |
31.0
50.8%
|
23.7
38.9%
|
16.7
26.9%
|
19.0
30.6%
|
34.5
56.6%
|
Remained the Same |
43.1
70.7%
|
40.7
66.7%
|
41.7
67.3%
|
51.7
83.4%
|
22.4
36.7%
|
Slightly Decreased |
13.8
22.6%
|
15.3
25.1%
|
20.0
32.3%
|
19.0
30.6%
|
8.6
14.1%
|
Moderately Decreased |
3.4
5.6%
|
5.1
8.4%
|
6.7
10.8%
|
1.7
2.7%
|
1.7
2.8%
|
Greatly Decreased |
0.0
0%
|
1.7
2.8%
|
3.3
5.3%
|
0.0
0%
|
0.0
0%
|
Title | Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score |
---|---|
Description | The investigator compared the participant's scalp hair growth at Month 6 to a photograph of the scalp taken at Baseline and using the 7-point IGA score, the investigator answered the question: "Since the start of the study, the amount of the subject's hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented. |
Time Frame | Baseline, Month 6 |
Outcome Measure Data
Analysis Population Description |
---|
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure. |
Arm/Group Title | Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution |
---|---|---|---|---|---|
Arm/Group Description | Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of minoxidil 5% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months. |
Measure Participants | 58 | 59 | 61 | 58 | 58 |
Greatly Increased |
0.0
0%
|
5.1
8.4%
|
0.0
0%
|
0.0
0%
|
8.6
14.1%
|
Moderately Increased |
12.1
19.8%
|
6.8
11.1%
|
4.9
7.9%
|
6.9
11.1%
|
24.1
39.5%
|
Slightly Increased |
29.3
48%
|
28.8
47.2%
|
23.0
37.1%
|
25.9
41.8%
|
15.5
25.4%
|
Remained the Same |
48.3
79.2%
|
55.9
91.6%
|
63.9
103.1%
|
63.8
102.9%
|
44.8
73.4%
|
Slightly Decreased |
10.3
16.9%
|
3.4
5.6%
|
8.2
13.2%
|
3.4
5.5%
|
6.9
11.3%
|
Moderately Decreased |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
Greatly Decreased |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
Title | Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score |
---|---|
Description | At the completion of the study, 3 independent dermatologists using the 7-point GPR score compared photographs of the participant's scalp hair growth at Month 6 to Baseline and answered the question: "Compared with the baseline image, the amount of the subject's hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented. |
Time Frame | Baseline, Month 6 |
Outcome Measure Data
Analysis Population Description |
---|
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure. |
Arm/Group Title | Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution |
---|---|---|---|---|---|
Arm/Group Description | Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of minoxidil 5% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months. |
Measure Participants | 57 | 56 | 58 | 56 | 58 |
Greatly Increased |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
Moderately Increased |
3.5
5.7%
|
1.8
3%
|
0.0
0%
|
0.0
0%
|
5.2
8.5%
|
Slightly Increased |
17.5
28.7%
|
10.7
17.5%
|
8.6
13.9%
|
8.9
14.4%
|
39.7
65.1%
|
Remained the Same |
71.9
117.9%
|
73.2
120%
|
74.1
119.5%
|
75.0
121%
|
50.0
82%
|
Slightly Decreased |
7.0
11.5%
|
14.3
23.4%
|
17.2
27.7%
|
16.1
26%
|
3.4
5.6%
|
Moderately Decreased |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
1.7
2.8%
|
Greatly Decreased |
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
0.0
0%
|
Title | Change From Baseline in Target Area Hair Width (TAHW) |
---|---|
Description | Digital imaging analysis was used to measure TAHW in millimeters/centimeters squared (mm/cm^2). The diameters of all terminal hairs (individual hairs ≥ 30 microns in width) in the target area were summed and reported together. A positive change from Baseline indicated improvement (increase in the diameter of terminal hairs). |
Time Frame | Baseline, Month 6 |
Outcome Measure Data
Analysis Population Description |
---|
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure. |
Arm/Group Title | Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution |
---|---|---|---|---|---|
Arm/Group Description | Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of minoxidil 5% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months. |
Measure Participants | 60 | 61 | 61 | 61 | 61 |
Baseline |
7.83
(3.879)
|
8.34
(3.716)
|
8.59
(3.668)
|
8.35
(3.494)
|
7.82
(3.436)
|
Change from Baseline at Month 6 |
0.76
(1.390)
|
0.25
(1.185)
|
0.12
(1.228)
|
0.13
(0.839)
|
1.29
(1.117)
|
Title | Change From Baseline in Target Area Hair Darkness (TAHD) |
---|---|
Description | Digital imaging analysis was used to measure TAHD. The darkness of all terminal hairs (individual hairs ≥ 30 microns in width) in the target area were summed and divided by total number of terminal hairs in the same target area and was reported as intensity units. A positive change from Baseline indicated improvement (increase in the darkness of terminal hairs). |
Time Frame | Baseline, Month 6 |
Outcome Measure Data
Analysis Population Description |
---|
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure. |
Arm/Group Title | Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution |
---|---|---|---|---|---|
Arm/Group Description | Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of minoxidil 5% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months. |
Measure Participants | 60 | 61 | 61 | 61 | 61 |
Baseline |
106.88
(19.282)
|
103.85
(21.950)
|
100.81
(18.041)
|
104.03
(17.863)
|
99.57
(28.139)
|
Change from Baseline at Month 6 |
1.19
(12.000)
|
2.92
(14.686)
|
4.04
(11.061)
|
0.65
(10.626)
|
3.40
(12.888)
|
Adverse Events
Time Frame | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Adverse Event Reporting Description | The Safety Population, that consisted of all participants who received at least 1 dose of study treatment, was used to calculate the number of participants at risk for treatment-emergent Serious Adverse Events and treatment-emergent Adverse Events. | |||||||||
Arm/Group Title | Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution | |||||
Arm/Group Description | Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. | Approximately one mL of minoxidil 5% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months. | |||||
All Cause Mortality |
||||||||||
Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution | ||||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | |||||
Serious Adverse Events |
||||||||||
Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution | ||||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/61 (0%) | 1/61 (1.6%) | 1/62 (1.6%) | 1/62 (1.6%) | 0/61 (0%) | |||||
Injury, poisoning and procedural complications | ||||||||||
Femur fracture | 0/61 (0%) | 0/61 (0%) | 1/62 (1.6%) | 0/62 (0%) | 0/61 (0%) | |||||
Humerus fracture | 0/61 (0%) | 0/61 (0%) | 1/62 (1.6%) | 0/62 (0%) | 0/61 (0%) | |||||
Radius fracture | 0/61 (0%) | 0/61 (0%) | 1/62 (1.6%) | 0/62 (0%) | 0/61 (0%) | |||||
Tibia fracture | 0/61 (0%) | 0/61 (0%) | 1/62 (1.6%) | 0/62 (0%) | 0/61 (0%) | |||||
Wrist fracture | 0/61 (0%) | 0/61 (0%) | 1/62 (1.6%) | 0/62 (0%) | 0/61 (0%) | |||||
Musculoskeletal and connective tissue disorders | ||||||||||
Back pain | 0/61 (0%) | 1/61 (1.6%) | 0/62 (0%) | 0/62 (0%) | 0/61 (0%) | |||||
Osteonecrosis | 0/61 (0%) | 0/61 (0%) | 0/62 (0%) | 1/62 (1.6%) | 0/61 (0%) | |||||
Other (Not Including Serious) Adverse Events |
||||||||||
Bimatoprost Formulation A | Bimatoprost Formulation B | Bimatoprost Formulation C | Vehicle to Bimatoprost | Minoxidil 5% Solution | ||||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 6/61 (9.8%) | 11/61 (18%) | 4/62 (6.5%) | 7/62 (11.3%) | 10/61 (16.4%) | |||||
General disorders | ||||||||||
Application site pruritis | 1/61 (1.6%) | 4/61 (6.6%) | 0/62 (0%) | 0/62 (0%) | 7/61 (11.5%) | |||||
Infections and infestations | ||||||||||
Nasopharyngitis | 5/61 (8.2%) | 7/61 (11.5%) | 4/62 (6.5%) | 7/62 (11.3%) | 3/61 (4.9%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
Name/Title | Therapeutic Area Head, |
---|---|
Organization | Allergan, Inc |
Phone | 714-246-4500 |
clinicaltrials@allergan.com |
- 192024-057
- 2011-000379-15